Skip to main content

Efficacy and safety of anti-IL-4Rα stapokibart for adults with moderate-to-severe prurigo nodularis: results from a phase 3 randomized trial

In brief

Stapokibart doubled meaningful itch relief in adults with prurigo nodularis

In a 200-person phase 3 trial in China, 64% of adults receiving stapokibart had at least a 4-point itch improvement after 24 weeks, compared with 33% on placebo; 45% also had clear or almost clear skin, versus 14%. Side effects were similar between groups, but whether the results apply beyond Chinese patients remains unknown.

Journal
Journal of the American Academy of Dermatology (Q1)
Published
19 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Li Zhang, Guannan Zhu, Jingyi Li, Litao Zhang, Guohong Hu, Liming Wu, et al.
PMID
43057472
DOI
10.1016/j.jaad.2026.11.053

Why clinicians should know about it

  • Picked for Dermatology (paper of the day, 20 November 2026): Phase 3 biologic trial for inflammatory skin disease

Abstract

BACKGROUND: Prurigo nodularis (PN) is a chronic inflammatory skin disease with limited treatment options. OBJECTIVE: To evaluate the efficacy and safety of anti-IL-4Rα stapokibart in adults with moderate-to-severe PN. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled phase 3 study (NCT06424470) conducted in 39 centers in China between June 24, 2024, and April 14, 2025. Eligible patients who had a diagnosis of PN for ≥3 months were randomly assigned 1:1 to receive subcutaneous stapokibart 300 mg (a loading dose, 600 mg) or placebo every 2 weeks for 24 weeks. RESULTS: Totally 200 patients were enrolled (n=100 per group). At week 24, significantly greater proportions of stapokibart-treated patients versus placebo achieved ≥4-point improvement in Worst Itch Numeric Rating Scale (64.0% vs. 33.0%; primary endpoint) and Investigator's Global Assessment for chronic nodular prurigo stage score of 0/1 (45.0% vs. 14.0%; key secondary endpoint) (both P<0.0001). Benefits were also observed in patients' quality of life, skin pain, sleep disturbance, and anxiety/depression. The incidence of treatment-emergent adverse events was similar between the stapokibart and placebo groups (79.0% vs. 73.0%). LIMITATION: Chinese patients only. CONCLUSION: 24 weeks of treatment with stapokibart demonstrated high efficacy and favorable safety in adults with moderate-to-severe PN.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.